ClinicalTrials.gg
Drug

Feladilimab clinical trials

studies test it
8
open now
0
in phase 3
2
first study started
2016

How each study uses feladilimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Feladilimab
7

Development codes

GSK3359609
1

Studies by the year they started

8 studies that test it; most in 2019 (4)

Studies that test feladilimab, by start year
YearStudies
20161
20181
20194
20201
20211

By phase

A phase 1/2 study counts in both.

Phase 1
3
Phase 2
5
Phase 3
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 8 · Other 0

GlaxoSmithKline (8)

Often tested with

Tested in the same studies.

Belantamab mafodotin (1) · Docetaxel (1) · Belrestotug (1) · Nelistotug (1)

Studies

Open first, then newest update. How each study uses feladilimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 8

Given beside what is tested · 2 — feladilimab is usual care or a partner of the new treatment

Codes

What other systems call feladilimab · ClinicalTrials.gg INT017500

  • UNII (FDA) OUP4QB2A3RFELADILIMABOne source FDA
  • NCI Thesaurus C126804FeladilimabOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.